Is Teva Pharmaceutical (TEVA) Trading at a Discount?
Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference ...
Piper Sandler Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)
In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...
Teva Pharmaceutical Industries Ltd: Putting Patients First: Why Europe Must Act to Protect Access To Medicines
New research by Teva Pharmaceuticals Europe shows that 46% of generic medicines from the EU Critical List of Medicines are supplied by only one provider. This ...
Pharmaceutical Technology on MSN1d
Teva and Alvotech launch ustekinumab biosimilar injection in US
Teva Pharmaceuticals and Alvotech have announced the US launch of Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.
Teva share price struggles to recover following $6 billion market loss
The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...
Gastric Cancer Global Market Report 2025: Impressive Global Market Trends And Leading Industry Players In Oncology
The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!